Log In
Print
BCIQ
Print
Print this Print this
 

amatuximab (MORAb-009)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionIgG1 antibody against glycoprotein-9 (GP-9; CD42a)
Molecular Target Glycoprotein-9 (GP-9) (CD42a)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMesothelioma
Indication DetailsTreat locally advanced malignant pleural mesothelioma (MPM); Treat malignant pleural mesothelioma (MPM)
Regulatory Designation

U.S. - Orphan Drug (Treat malignant pleural mesothelioma (MPM));
EU - Orphan Drug (Treat malignant pleural mesothelioma (MPM))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today